RecruitingInterventional · Phase 1NCT02074839 ↗A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Active, not recruitingInterventional · Phase 1/2NCT02106598 ↗Targeted Silica Nanoparticles for Real-Time Image-Guided Intraoperative Mapping of Nodal MetastasesDavid I. KutlerPIInterventionDrug: fluorescent cRGDY-PEG-Cy5.5-C dotsDatesApr 2014 – Apr 2027 (est.)SponsorMemorial Sloan Kettering Cancer CenterHead and Neck Melanoma
Active, not recruitingInterventional · Phase 3NCT02193282 ↗Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)Ashish SaxenaPIInterventionOther: Clinical Observation · Drug: Erlotinib Hydrochloride · Other: Laboratory Biomarker Analysis · Other: Placebo AdministrationDatesFeb 2015 – Dec 2025SponsorAlliance for Clinical Trials in OncologyLung Non-Squamous Non-Small Cell CarcinomaStage IB Lung Non-Small Cell Carcinoma AJCC v7Stage II Lung Non-Small Cell Cancer AJCC v7+3 more
Active, not recruitingInterventional · Phase 2NCT02365597 ↗A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects With Metastatic or Surgically Unresectable Urothelial Cancer With FGFR Genomic AlterationsScott T. TagawaPIInterventionDrug: Erdafitinib · Drug: Midazolam · Drug: MetforminDatesApr 2015 – Sep 2022· Results postedSponsorJanssen Research & Development, LLCUrothelial Cancer
RecruitingInterventional · Phase 2NCT02523014 ↗Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway MutationsRajiv S. MaggePIInterventionDrug: Vismodegib · Drug: FAK Inhibitor GSK2256098 · Drug: Capivasertib · Drug: AbemaciclibDatesSep 2015 – Jun 2028 (est.)SponsorAlliance for Clinical Trials in OncologyIntracranial MeningiomaRecurrent MeningiomaNF2 Gene Mutation
RecruitingInterventional · Phase 3NCT02582697 ↗Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell TumoursAlexander Ja-Ho ChouPIInterventionDrug: Bleomycin (active name: Bleomycin Sulfate) · Drug: Etoposide · Drug: Cisplatin · Drug: Pegylated G-CSF (Pegfilgrastim) · Drug: FilgrastimDatesFeb 2014 – Dec 2029 (est.)SponsorChildren's Oncology GroupGerm Cell Tumor
Active, not recruitingInterventional · Phase 2/3NCT02598661 ↗A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) TreatmentPinkal DesaiPIInterventionDrug: Imetelstat Sodium · Drug: PlaceboDatesJan 2016 – Oct 2023· Results postedSponsorGeron CorporationMyelodysplastic Syndromes
Active, not recruitingInterventional · Phase 1NCT02732275 ↗A Phase 1 Multiple Ascending Dose Study of DS-3201b in Subjects With LymphomasJia RuanPIInterventionDrug: DS-3201bDatesMar 2016 – Dec 2022SponsorDaiichi Sankyo, Inc.Lymphoma, MalignantNon-hodgkin Lymphoma
Active, not recruitingInterventional · Phase 1/2NCT02773030 ↗Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 As Monotherapy and in Combination With Other Treatments in Subjects With Multiple MyelomaRuben NiesvizkyPIInterventionDrug: CC-220 · Drug: Dexamethasone · Drug: Daratumumab · Drug: Bortezomib · Drug: Carfilzomib · Drug: Daratumumab - 16mg/kg · Drug: Bortezomib (BTZ) · Drug: Daratumumab- 1800mgDatesOct 2016 – May 2024· Results postedSponsorCelgene CorporationMultiple Myeloma
Active, not recruitingInterventional · Phase 1NCT02886065 ↗A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Citarinostat (CC-96241), a Histone Deacetylase Inhibitor (HDAC) With and Without Lenalidomide for Patients With Smoldering Multiple MyelomaRuben NiesvizkyPIInterventionDrug: Hiltonol · Drug: Citarinostat · Drug: Lenalidomide · Biological: PVX-410DatesMar 2017 – Feb 2027 (est.)SponsorDana-Farber Cancer InstituteSmoldering Multiple Myeloma
RecruitingInterventional · Phase 2NCT02974647 ↗Phase II Multicenter Study of Ruxolitinib in Relapsed or Refractory T or NK Cell LymphomaJia RuanPIInterventionDrug: RuxolitinibDatesNov 2016 – Nov 2027 (est.)SponsorMemorial Sloan Kettering Cancer CenterLymphoma
Active, not recruitingInterventional · Phase 1NCT03091257 ↗An Open-label, Pilot Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple MyelomaRuben NiesvizkyPIInterventionDrug: Dabrafenib · Drug: TrametinibDatesJun 2017 – Jul 2026SponsorDana-Farber Cancer InstituteMultiple Myeloma
Active, not recruitingInterventional · Phase 2NCT03092856 ↗Phase II Randomized Double Blind Trial of PF-04518600, an OX40 Antibody, in Combination With Axitinib Versus Axitinib in Immune-Checkpoint Inhibitor Exposed Patients With Metastatic Renal Cell CarcinomaAna M. MolinaPIInterventionBiological: Anti-OX40 Antibody PF-04518600 · Drug: Axitinib · Other: Laboratory Biomarker Analysis · Other: PlaceboDatesJul 2017 – Dec 2026 (est.)SponsorUSC Keck School of Medicine Norris Cancer CenterClear Cell Renal Cell CarcinomaMetastatic Renal Cell CancerRecurrent Renal Cell Carcinoma+1 more
Active, not recruitingInterventional · Phase 3NCT03105102 ↗A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's DiseaseAliza B SolomonPIInterventionDrug: Placebo for Risankizumab SC · Drug: Risankizumab IV · Drug: Placebo for Risankizumab IV · Drug: Risankizumab SC · Drug: Risankizumab On-Body Injector (OBI)DatesApr 2018 – Feb 2029 (est.)SponsorAbbVie Inc.Crohn's Disease
Active, not recruitingInterventional · Phase 3NCT03301506 ↗ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)Sonal KumarPIInterventionDrug: Seladelpar 5 mg Capsule · Drug: Seladelpar 10 mg CapsuleDatesDec 2017 – Nov 2028 (est.)SponsorGilead Sciences, Inc.Primary Biliary Cirrhosis
Active, not recruitingInterventional · Phase 1/2NCT03304080 ↗A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast CancerEleni AndreopoulouPIInterventionDrug: Anastrozole · Drug: Palbociclib · Drug: Trastuzumab · Drug: PertuzumabDatesDec 2017 – Jul 2027 (est.)SponsorIcahn School of Medicine at Mount SinaiBreast NeoplasmsBreast Diseases
Active, not recruitingInterventional · Phase 4NCT03315910 ↗Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening SitesBradley B PuaPIInterventionBehavioral: Motivational Interviewing (MI) · Drug: Nicotine Replacement Therapy (NRT) · Drug: Nicotine Lozenge · Behavioral: Message Framing · Other: saliva sampleDatesOct 2017 – Oct 2027 (est.)SponsorMemorial Sloan Kettering Cancer CenterSmoking Cessation
Active, not recruitingInterventional · Phase 2NCT03371719 ↗A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)Hani Lamie AshamallaPIInterventionDrug: Apalutamide · Radiation: External Beam Radiation Therapy · Other: Placebo AdministrationDatesJun 2018 – Mar 2025· Results postedSponsorNRG OncologyRecurrent Prostate CarcinomaStage III Prostate Adenocarcinoma AJCC v7Stage IV Prostate Adenocarcinoma AJCC v7
Active, not recruitingInterventional · Phase 2NCT03375307 ↗A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors With DNA-Repair DefectsCora SternbergPIInterventionProcedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Bone Marrow Biopsy · Procedure: Bone Scan · Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging · Drug: Olaparib · Procedure: Positron Emission TomographyDatesNov 2020 – Dec 2026 (est.)SponsorNational Cancer InstituteAdvanced Bladder CarcinomaAdvanced Genitourinary System CarcinomaMetastatic Bladder Carcinoma+3 more
Active, not recruitingInterventional · Phase 2NCT03407144 ↗An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults With Newly Diagnosed Classical Hodgkin Lymphoma With Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)Lisa Giulino RothPIInterventionBiological: pembrolizumab · Drug: doxorubicin · Drug: vinblastine · Drug: dacarbazine · Drug: cyclophosphamide · Drug: vincristine · Drug: prednisone/prednisolone · Drug: bleomycin · Drug: etoposide · Radiation: Radiotherapy (RT)DatesApr 2018 – Feb 2027 (est.)SponsorChildren's Oncology GroupHodgkin Lymphoma